Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12119814 | 0.81 | CYP2D6 (0.39) | CYP2D6CYP2C19MMP1MMP8MTNR1A | |
| SCHEMBL24919756 | 0.79 | ALDH1A1 (0.39) | CYP2D6CYP2C19MTNR1AMTNR1BEPHX1 | |
| SCHEMBL91326 | 0.78 | — | — | |
| SCHEMBL25086839 | 0.77 | CYP2D6 (0.46) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL22959001 | 0.77 | ALDH1A1 (0.39) | CYP2D6CYP2C19MMP1MMP8MTNR1A | |
| Hydrochloric Acid SCHEMBL30777456 | 0.76 | — | — | |
| SCHEMBL9462565 | 0.75 | MAPK1 (0.49) | CYP2D6CYP2C19MMP1MMP8HPGD | |
| SCHEMBL10062233 | 0.73 | MTNR1A (0.44) | CYP2D6CYP2C19MMP1MMP8MTNR1A | |
| SCHEMBL14953743 | 0.72 | ALDH1A1 (0.39) | CYP2D6CYP2C19MTNR1AMTNR1BALDH1A1 | |
| SCHEMBL8436494 | 0.72 | TSHR (0.42) | CYP2D6CYP2C19MTNR1AMTNR1BEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | CYP2D6 1366/4885CYP2C19 1451/4885MMP1 4640/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | CYP2D6 1366/4885CYP2C19 1451/4885MMP1 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.